Alto Neuroscience, Inc. ANRO 深 滬
等待開盤 07-22 09:30:00 美东时间
2.75
-0.030
-1.08%
華盛通- 最 高2.87
- 今 開2.79
- 成交量 3.15万股
- 最 低 2.75
- 昨 收 2.78
- 總市值 7444.83万
- 52周最高 15.04
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 1.60
- 委 比 6.38%
- 總股本 2707.21万
- 歷史最高 24.00
- 量 比 0.44
- 振 幅 4.32%
- 歷史最低 1.60
- 每 手 1
- 風險率 4.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
Alto Neuroscience Identifies EEG Biomarker And Reports Pharmacodynamic Results From Phase 2 Trial Of ALTO-203 For Major Depressive Disorder
Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control ALTO-203, a non-stimulant compound which demonstrated
06-26 19:37
Alto Neuroscience Acquires Assets from Chase Therapeutics
An announcement from Alto Neuroscience, Inc. ( ($ANRO) ) is now available. On M...
06-03 18:58
Alto Buys Depression and Parkinson's Drug Portfolio for $1.75M Upfront, With $71.5M in Future Milestones
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an
06-03 18:05
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Wedbush Reiterates Neutral on Alto Neuroscience, Maintains $4 Price Target
Wedbush analyst Laura Chico reiterates Alto Neuroscience (NYSE:ANRO) with a Neutral and maintains $4 price target.
05-15 22:49
Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.61) by 8.2 percent. This is a 26.32 percent increase over losses of $(0.76) per share from the
05-15 04:25
美股机会日报丨恐慌情绪缓解！三大股指期货盘前走高；马斯克向特朗普发出撤销新关税呼吁
恐慌情绪缓解！三大股指期货盘前走高，纳指期货涨超2%；内部分歧加大？马斯克向特朗普发出撤销新关税呼吁；特朗普将签署行政命令，推动煤炭行业发展，美股煤炭股盘前拉升>>
04-08 20:23
美股大行评级 | 潜在涨幅102.31%！瑞穗上调Amylyx制药目标价至7美元，评级升至"跑赢大市"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116286800185102336.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 瑞穗：上调Amylyx Pharmaceuticals(AMLX)评级至"跑赢大市"，目标价从3美元升至7美元</p> <p>• Redburn Atlantic：上调Roku(ROKU)评级至"买入"，目标价100美元<
04-08 10:08
